Personalized Antisense Oligonucleotide Therapy for A Single Participant With ASXL3 Gene Mutation
Clinical trial NCT07197268 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07197268
- Sponsor
- n-Lorem Foundation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-19
- Primary completion
- 2027-05-01
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.